# US 2024/0197749 A1 · Method of inhibiting lipogenesis with ubiquitin-specific peptidase 24 inhibitor composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197749 A1
- Document ID: US20240197749A1
- Status: Published application
- Kind: A1
- Application number: 18/498,472
- Filed: 2023-10-31
- Published: 2024-06-20
- Earliest claimed: 2022-11-25
- Assignees: National Cheng Kung University
- Applicants: National Cheng Kung University
- Inventors: Chien-Chung HUNG
- Web page: https://patentgrep.com/patent/US20240197749A1

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61P 3/06: Antihyperlipidemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of inhibiting lipogenesis with a ubiquitin-specific peptidase 24 (USP24) inhibitor composition. The USP24 inhibitor composition, which includes a carbonyl substituted phenyl compound, can specifically inhibit lipogenesis and hepatic lipid accumulation in a high-fat individual, thereby being applied to a method of inhibiting lipogenesis and hepatic lipid accumulation in a high-fat subject.

## Claims

### Claim 1

A method of inhibiting lipogenesis with a ubiquitin-specific peptidase (USP) 24 inhibitor composition, wherein the USP 24 inhibitor composition comprises carbonyl-substituted phenyl compound and/or its salt as an active ingredient, as shown in formula (I):
in formula (I), X1 represents a single bond, n1 represents an integer of 1 or 2, Y represents a monovalent group, X2 represents a hydrogen atom or a hydroxyl group, and the salts of said carbonyl-substituted phenyl compound are selected from a group consisting of oxalates, phosphates, sulfates, and hydrochlorides, and
wherein when X1 represents the single bond, n1 represents the integer 1, in formula (I-1), R1 represents an alkyl piperazine group as shown in formula (I-2), where # represents a connecting point with one nitrogen atom of the thiazine group (I-1), and n2 represents an integer from 1 to 4:
wherein when X2 represents a hydrogen atom, Y represents a monovalent group having a thiazine group as shown in formula (I-1), and * in formula (I-1) represents a connecting point with X1

### Claim 2 (depends on 1)

The method according to claim 1, wherein the carbonyl-substituted phenyl compound has a structure as shown in either formula (I-3-1) or formula (I-3-3):

### Claim 3 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition further includes a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered in vitro to a test subject, and the test subject is a fat cell, pre-fat cell, and/or adipocyte-like cell.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the carbonyl-substituted phenyl compound is administered to the test subject in vitro at an effective dose of 1 μM to 20 μM.

### Claim 6

A method of inhibiting hepatic lipid accumulation with a USP 24 inhibitor composition, wherein the USP 24 inhibitor composition comprises carbonyl-substituted phenyl compound and/or its salt as an active ingredient, as shown in formula (I):
in formula (I), X1 represents a single bond, n1 represents an integer of 1 or 2, Y represents a monovalent group, X2 represents a hydrogen atom or a hydroxyl group, and the salts of said carbonyl-substituted phenyl compound are selected from a group consisting of oxalates, phosphates, sulfates, and hydrochlorides, and
wherein when X1 represents the single bond, n1 represents the integer 1, in formula (I-1), R1 represents an alkyl piperazine group as shown in formula (I-2), where # represents a connecting point with one nitrogen atom of the thiazine group (I-1), and n2 represents an integer from 1 to 4
wherein when X2 represents a hydrogen atom, Y represents a monovalent group having a thiazine group as shown in formula (I-1), and * in formula (I-1) represents a connecting point with X1,
wherein the carbonyl-substituted phenyl compound is administered to an individual at an effective dose of 5 mg/kg body weight to 20 mg/kg body weight.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the individual has hyperlipidemia.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the individual is a mouse.

### Claim 9

A method of inhibiting the expression of PPAR-γ and/or PLIN1 genes with a USP 24 inhibitor composition, wherein the USP 24 inhibitor composition comprises carbonyl-substituted phenyl compound and/or its salt as an active ingredient, as shown in formula (I-3-1):
thereby reducing the expression levels of PPAR-γ and/or PLIN1 genes in test cells.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the test subject is a 3T3-L1 cell, a differentiated adipocyte derived from a 3T3-L1 cell, and/or a differentiated adipocyte-like cell derived from a 3T3-L1 cell.
